Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

ClinicalTrials.gov ID: NCT00003715

Public ClinicalTrials.gov record NCT00003715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b

Study identification

NCT ID
NCT00003715
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
AVAX Technologies
Industry
Enrollment
425 participants

Conditions and interventions

Interventions

  • BCG vaccine Biological
  • autologous tumor cell vaccine Biological
  • recombinant interferon alfa Biological
  • chemotherapy Drug
  • cyclophosphamide Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years to 120 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 1998
Primary completion
Not listed
Completion
Not listed
Last update posted
Dec 2, 2015

Started 1998

United States locations

U.S. sites
17
U.S. states
13
U.S. cities
16
Facility City State ZIP Site status
Cancer and Blood Institute of the Desert Rancho Mirage California 92270
Yale Comprehensive Cancer Center New Haven Connecticut 06520-8028
Columbia - HCA Cancer Research Network North Miami Beach Florida 33180
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612
Georgia Cancer Specialists Decatur Georgia 30033
University of Illinois at Chicago Chicago Illinois 60612
Lutheran General Cancer Care Center Park Ridge Illinois 60068
James Graham Brown Cancer Center Louisville Kentucky 40202
Cancer and Hematology Centers of Western Michigan Grand Rapids Michigan 49546
Hubert H. Humphrey Cancer Center Robbinsdale Minnesota 55422
Midwest Oncology Consortium Kansas City Missouri 64111
Jersey Shore Cancer Center Neptune City New Jersey 07753
Cancer Institute of New Jersey New Brunswick New Jersey 08901
Herbert Irving Comprehensive Cancer Center New York New York 10032
University of Pennsylvania Cancer Center Philadelphia Pennsylvania 19104
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia Philadelphia Pennsylvania 19107
Palmetto Hematology/Oncology Associates Spartanburg South Carolina 29303

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 2, 2015 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00003715 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →